New Triple-Action antibody takes on Hard-to-Treat myeloma
NCT ID NCT06375044
First seen Nov 16, 2025 · Last updated May 13, 2026 · Updated 24 times
Summary
This early-phase trial tests a new drug called SIM0500 in about 130 adults with multiple myeloma that has come back or stopped responding to standard treatments. The drug is designed to help the immune system attack cancer cells from three different angles. The main goal is to check safety and find the best dose, while also seeing if it can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Beijing Chaoyang Hospital Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact
-
Dana Farber Cancer institution
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450000, China
Contact
-
Icahn School of Medicine at Mount Sinai，The Tisch Cancer Institute
RECRUITINGNew York, New York, 10029, United States
Contact
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300000, China
Contact
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact
-
Mayo Clinic Arizona
RECRUITINGPhoenix, Arizona, 85054, United States
Contact Phone: •••-•••-••••
Contact
-
Mayo Clinic Florida
RECRUITINGJacksonville, Florida, 32224, United States
Contact Phone: •••-•••-••••
Contact
-
Mayo Clinic Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-••••
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact
-
The First Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHanzhou, Zhejiang, 310000, China
Contact
Conditions
Explore the condition pages connected to this study.